4 min readDesigning Anew: Radical COVID-19 Drug Development Approach Shows Promise
Austin, TX — Nearly every drug that is, or has ever been, used was derived from nature — harnessing compounds created by organisms over eons to fight diseases. But decades ago, biochemists postulated that it might be possible to design a new drug from scratch by linking up amino acids in precise ways.
The tricky part, as it turned out, was predicting in advance how the amino acids in a protein would fold. The folded form determines the three-dimensional shape of the protein, as well as its electrostatic potential, and hydrophobicity (the degree to which a molecule is repelled from a mass of water) — factors that are critical when it comes to designing an effective drug.
David Baker, professor of Biochemistry at the University of Washington and head of the Institute for Protein Design there, pioneered methods for using computers to predict how proteins fold. Based on that knowledge, he and his team have designed new, never-before-seen proteins for use as drugs, sensors, or even biological logic gates.
This approach is known as de novo protein design. There are currently only a few drugs in trial that have used this approach, but it holds incredible potential — and at no time has such an approach been more critical than now.
The platform that the Institute for Protein Design developed allows for the rapid design of protein binders to target proteins of interest. Computer (in silico) simulations generate a library of candidate protein sequences that are then tested at their in-house testing facility. Promising candidates are evolved both in silico and in the wet lab until a final binding protein is created.
Starting in January, researchers in the Baker Lab began have been using their methodology to design a drug or vaccine to treat COVID-19. Their studies involve calculating the three-dimensional shape of millions of possible proteins, and then computationally testing how such proteins would fit into, and dock with, parts of the SARS-CoV-2 virus.
To assist in this effort, they are using the Stampede2 supercomputer at the Texas Advanced Computing Center (TACC) — one of the fastest in the world — as well as the network of volunteer computers known as Rosetta@Home. (Rosetta is the name of the software developed in the Baker Lab to predict protein folding and to design new proteins.)
“In just a two-month span, our team has been able to computationally design millions of protein therapeutics that target the seven major proteins related to COVID-19,” Baker reported in March.
To date, 733,000 proteins have been ordered, 323,000 of these protein therapeutics have been tested in the laboratory, and more than 2,000 have shown binding signals to their respective targets.
From Scaffolds to Protein Structures
The team began by testing its collection of 20,000 scaffold proteins that form the starting point for future drugs or vaccines. Each can be docked in over 1,000 orientations; and each dock is subsampled 1,000 times with slight perturbations – leading to 20 billion potential interactions to compute.
“In the scaffold phase, we’re looking for signs these are going to be atomically accurate,” said Brian Coventry, a PhD student in the group working on the project. “If we’re off by 0.1 nanometers, there’s no way it will work. These things have to be perfect.”
The top 1 million of these docks then move forward to sequence design where each position on the scaffold backbone must be assigned an amino acid. With 20 amino acid choices at each position, and a variety of conformations for each, the computer must solve the combinatorial explosion to assign the best combination of amino acids to each scaffold.
From the 1 million designed proteins, they determine the most promising subset – roughly 100,000 proteins. The team sends a text file containing DNA sequences for these candidates to Agilent, a company that can create synthetic DNA molecules on demand. Agilent returns test tubes with physical DNA, which is then inserted into yeast genomes in such a way that the various synthetic proteins are made and displayed on tethers from the cell membrane of yeast, allowing them to be tested against the virus.
Based on the initial computational and experimental results, the team then engages in site saturation mutagenesis, where each individual amino acid on the chain is mutated at every location and re-tested to see how it behaves.
“We get data back and look at what made a given protein better or worse. And we ask the question: ‘Does this protein look like it’s working for the right reasons?'” Coventry said.
Based on the results and insights from the mutagenesis, they go one step further and develop a combo library that includes degenerate codons, where alternate nucleotides replace the typical ones in a given amino acid.
The best combination of mutations and replacements undergo further experimental testing including bacterial expression and thermodynamic analysis. Using this method, they derived 50 highly promising leads for the spike protein binder from an initial screening of 100,000 proteins.
“The spike protein binder is the most likely to result in a drug because of its mechanism of action,” Coventry said.
But the ability to create designer proteins is not the lab’s only innovation, nor is a single binder their final goal. They are also pioneering a new approach to drugs called mini-protein binders that combine the specificity of antibodies with the high stability and manufacturability of small molecule drugs.
Mini-protein binders have been shown to have much greater stability at elevated temperatures and better neutralization than comparable antibodies and natural protein derivatives. They are also approximately 1/30th of the molecular weight of typical proteins, and can be synthesized chemically, which enables the introduction of a wide variety of functionalities. Probably as a result of their small size and very high stability, they elicit little immune response.
“We aim to connect four to six of the most potent neutralizers in a single chain by flexible linkers to achieve highly avid binding with little potential for escape,” Baker said in a presentation to the Defense Advanced Research Projects Agency (DARPA), one of the funders of the research.
“We try to get many binders and connect them with linkers,” Coventry explained further. “The idea is that you get an avidity effect” — the accumulated strength of multiple affinities. “At least one of those proteins will be binding at any given time and the virus particle won’t be able to escape the chain. Since the binders block the viral binding epitope, the virus will not be able to enter our cells.”
Article adapted from a University of Texas at Austin, Texas Advanced Computing Center news release.